SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 8, 2000
IMMTECH INTERNATIONAL, INC.
--------------------------------------------------------------------------------
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
Delaware 000-25669 39-1523370
--------------------------------------------------------------------------------
(STATE OR OTHER (COMMISSION FILE NUMBER) (I.R.S. EMPLOYER
JURISDICTION OF IDENTIFICATION NO.)
INCORPORATION)
150 Fairway Drive, Suite 150, Vernon Hills, Illinois 60061
--------------------------------------------------------------------------------
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
Registrant's telephone number, including area code: (847) 573-0033
Not Applicable
--------------------------------------------------------------------------------
(FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)
<PAGE>
Item 5. Other Events.
(A) Consummation of Private Placements
----------------------------------
Immtech International, Inc. ("Immtech"), announced recently the
consummation of two private placements of its common stock - one to accredited
investors in the U.S. in reliance on Regulation D under the Securities Act of
1933, as amended, and one to offshore investors in reliance on Regulation S
under the Securities Act of 1933, as amended. The two private placements
collectively resulted in Immtech selling an aggregate of 584,250 shares of its
common stock for gross proceeds of $4,674,000.
A press release was issued by Immtech containing a more detailed
description of the private placements, a copy of which is filed herewith as
Exhibit 99.1 and incorporated herein by reference.
(B) Grant by The Bill & Melinda Gates Foundation
--------------------------------------------
The Bill & Melinda Gates Foundation has awarded $15.11 million in
grants to a consortium led by The University of North Carolina at Chapel Hill
and Immtech to develop new drugs to treat African sleeping sickness and
leishmaniasis - two diseases that are infesting and killing millions of people
in developing nations.
Immtech's leading drug candidate for the treatment of African
sleeping sickness is a compound called DB289, which is also in the first phase
of human clinical trials for use as an anti-infective drug to treat Pneumocystis
carinii pneumonia, an opportunistic fungal infection that is potentially fatal
in immuno-suppressed patients.
The Bill & Melinda Gates Foundation was founded by Melinda Gates and
William H. Gates, III, of Microsoft Corporation.
A press release was issued by The University of North Carolina at
Chapel Hill describing the grant by The Bill & Melinda Gates Foundation, a copy
of which is filed herewith as Exhibit 99.2 and incorporated herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information, and Exhibits.
(c) The following exhibits are filed with this report:
Exhibit Number Description
-------------- -----------
99.1 Press Release of Immtech International, Inc., issued
December 8, 2000
99.2 Press Release of The University of North Carolina at Chapel
Hill, issued December 18, 2000
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
IMMTECH INTERNATIONAL, INC.
By: /s/ T. Stephen Thompson
----------------------------------------
Name: T. Stephen Thompson
Title: Chief Executive Officer and President
Dated: December 18, 2000
<PAGE>
EXHIBIT INDEX
Exhibit Number Description
-------------- -----------
99.1 Press Release of Immtech International, Inc., issued
December 8, 2000
99.2 Press Release of The University of North Carolina at Chapel
Hill, issued December 18, 2000
